IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (Review)
- Authors:
- Julia Durzyńska
-
Affiliations: Department of Molecular Virology, Institute of Experimental Biology, Faculty of Biology, Adam Mickiewicz University, 60-614 Poznań, Poland - Published online on: September 19, 2014 https://doi.org/10.3892/or.2014.3505
- Pages: 2295-2306
-
Copyright: © Durzyńska . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
 |
 |
|
Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Barton ER: The ABCs of IGF-I isoforms: impact on muscle hypertrophy and implications for repair. Appl Physiol Nutr Metab. 31:791–797. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Durzyńska J, Philippou A, Brisson BK, Nguyen-McCarty M and Barton ER: The pro-forms of insulin-like growth factor I (IGF-I) are predominant in skeletal muscle and alter IGF-I receptor activation. Endocrinology. 154:1215–1224. 2013.PubMed/NCBI | |
|
Tan DS, Cook A and Chew SL: Nucleolar localization of an isoform of the IGF-I precursor. BMC Cell Biol. 3:172002. View Article : Google Scholar : PubMed/NCBI | |
|
Durzyńska J, Wardziński A, Koczorowska M, Goździcka-Józefiak A and Barton ER: Human Eb peptide: not just a by-product of pre-pro-IGF1b processing? Horm Metab Res. 45:415–422. 2013.PubMed/NCBI | |
|
Siegfried JM, Kasprzyk PG, Treston AM, Mulshine JL, Quinn KA and Cuttitta F: A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone. Proc Natl Acad Sci USA. 89:8107–8111. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Kasprzak A, Szaflarski W, Szmeja J, et al: Expression of various insulin-like growth factor-1 mRNA isoforms in colorectal cancer. Contemp Oncol. 16:147–153. 2012. | |
|
Kasprzak A, Szaflarski W, Szmeja J, et al: Differential expression of IGF-1 mRNA isoforms in colorectal carcinoma and normal colon tissue. Int J Oncol. 42:305–316. 2013.PubMed/NCBI | |
|
Koczorowska MM, Kwasniewska A and Gozdzicka-Jozefiak A: IGF1 mRNA isoform expression in the cervix of HPV-positive women with pre-cancerous and cancer lesions. Exp Ther Med. 2:149–156. 2011.PubMed/NCBI | |
|
Pollak M: Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 8:915–928. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Grimberg A: Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther. 2:630–635. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lukanova A, Lundin E, Toniolo P, et al: Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer. 101:549–554. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A and Baserga R: Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 90:11217–11221. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett. 195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Loughran G, Huigsloot M, Kiely PA, Smith LM, Floyd S, Ayllon V and O’Connor R: Gene expression profiles in cells transformed by overexpression of the IGF-I receptor. Oncogene. 24:6185–6193. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gallagher EJ and LeRoith D: Minireview: IGF, insulin, and cancer. Endocrinology. 152:2546–2551. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Aleksic T, Chitnis MM, Perestenko OV, et al: Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res. 70:6412–6419. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Baserga R: The insulin receptor substrate-1: a biomarker for cancer? Exp Cell Res. 315:727–732. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Baserga R: Customizing the targeting of IGF-1 receptor. Future Oncol. 5:43–50. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
DePinho RA: The age of cancer. Nature. 408:248–254. 2000. View Article : Google Scholar | |
|
Laron Z: The GH-IGF1 axis and longevity. The paradigm of IGF1 deficiency. Hormones. 7:24–27. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Steuerman R, Shevah O and Laron Z: Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol. 164:485–489. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Laron Z: Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958–2003. J Clin Endocrinol Metab. 89:1031–1044. 2004.PubMed/NCBI | |
|
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al: Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 3:70ra132011.(Epub ahead of print). View Article : Google Scholar | |
|
Wang SR, Carmichael H, Andrew SF, et al: Large-scale pooled next-generation sequencing of 1077 genes to identify genetic causes of short stature. J Clin Endocrinol Metab. 98:1428–1437. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mullis PE: Genetics of isolated growth hormone deficiency. J Clin Res Pediatr Endocrinol. 2:52–62. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Forbes BE: Molecular mechanisms underlying insulin-like growth factor action: How mutations in the GH: IGF axis lead to short stature. Pediatr Endocrinol Rev. 8:374–381. 2011.PubMed/NCBI | |
|
Petriczko E, Wikiera B, Horodnicka-Józwa A, et al: A two year observation of the process of applying recombinant IGF-1 to treat short stature in children with primary IGF-1 deficiency - case reports of 3 patients. Pediatr Endocrinol Diabetes Metab. 17:233–238. 2011.PubMed/NCBI | |
|
Kędzia A, Durzyńska J, Gabryelczyk B, Petriczko E and Goździcka-Józefiak A: An analysis of the IGF-I receptor coding sequence in the genome of children with growth disorders. Pediatrc Endocrinol, Diabet and Metab. 19:96–99. 2013.PubMed/NCBI | |
|
Kasprzak A and Adamek A: The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (Review). Int J Oncol. 41:1919–1931. 2012.PubMed/NCBI | |
|
Trojanek J, Croul S, Ho T, et al: T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. J Cell Physiol. 206:35–46. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Reiss K, Khalili K, Giordano A and Trojanek J: JC virus large T-antigen and IGF-I signaling system merge to affect DNA repair and genomic integrity. J Cell Physiol. 206:295–300. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ramamoorthy S, Devaraj B, Miyai K, et al: John Cunningham virus T-antigen expression in anal carcinoma. Cancer. 117:2379–2385. 2011. View Article : Google Scholar | |
|
de Villiers EM, Fauquet C, Broker TR, Bernard HU and zur Hausen H: Classification of papillomaviruses. Virology. 324:17–27. 2004. | |
|
Jo H and Kim JW: Implications of HPV infection in uterine cervical cancer. Cancer Ther. 3:419–434. 2005. | |
|
Bernard HU: The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol. 32:S1–S6. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002.PubMed/NCBI | |
|
Pietsch EC and Murphy ME: Low risk HPV-E6 traps p53 in the cytoplasm and induces p53-dependent apoptosis. Cancer Biol Ther. 7:1916–1918. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 384:260–265. 2009.PubMed/NCBI | |
|
Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B and Tommasino M: The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 40:1–13. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 110:525–541. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR and Stanley MA: The biology and life-cycle of human papillomaviruses. Vaccine. 30:F55–F70. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Whiteside MA, Siegel EM and Unger ER: Human papillomavirus and molecular considerations for cancer risk. Cancer. 113:S2981–S2994. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
von Knebel Doeberitz M: New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 38:2229–2242. 2002.PubMed/NCBI | |
|
Vinokurova S, Wentzensen N, Kraus I, et al: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 68:307–313. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Thorland EC, Myers SL, Gostout BS and Smith DI: Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene. 22:1225–1237. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung JL, Cheung TH, Yu MY and Chan PK: Virological characteristics of cervical cancers carrying pure episomal form of HPV16 genome. Gynecol Oncol. 131:374–379. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yugawa T and Kiyono T: Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 19:97–113. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Egawa K: Do human papillomaviruses target epidermal stem cells? Dermatology. 207:251–254. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson VG, West M, Woytek K and Rangasamy D: Papillomavirus E1 proteins: form, function, and features. Virus Genes. 24:275–290. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
You J, Croyle JL, Nishimura A, Ozato K and Howley PM: Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell. 117:349–360. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Doorbar J: The papillomavirus life cycle. J Clin Virol. 32:S7–S15. 2005. View Article : Google Scholar | |
|
Watson RA, Thomas M, Banks L and Roberts SJ: Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci. 116:4925–4934. 2003. View Article : Google Scholar | |
|
Sun L, Zhang G, Lei T, Huang C, Song T and Si L: Two different HPV-11E6 fusion proteins trap p53 in the cytoplasm and induce apoptosis. Cancer Biol Ther. 7:1909–1915. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A and Zehbe I: The role of TP53 in cervical carcinogenesis. Hum Mutat. 21:307–312. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ganguly N and Parihar SP: Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci. 34:113–123. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
McLaughlin-Drubin ME and Münger K: The human papillomavirus E7 oncoprotein. Virology. 384:335–344. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Psyrri A and DiMaio D: Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol. 5:24–31. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Clifford GM, Smith JS, Plummer M, Muñoz N and Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 88:63–73. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 92:690–698. 2000.PubMed/NCBI | |
|
Lee SW, Lee SY, Lee SR, Ju W and Kim SC: Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia. Gynecol Oncol. 21:174–180. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR and Follen M: Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res. 9:3356–3361. 2003.PubMed/NCBI | |
|
Huang YF, Shen MR, Hsu KF, Cheng YM and Chou CY: Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br J Cancer. 99:1096–1102. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Schaffer A, Koushik A, Trottier H, et al: Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 16:716–722. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Serrano ML, Romero A, Cendales R, Sánchez-Gómez M and Bravo MM: Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica. 26:258–268. 2006. | |
|
Serrano ML, Sánchez-Gómez M and Bravo MM: Insulin-like growth factor system gene expression in cervical scrapes from women with squamous intraepithelial lesions and cervical cancer. Growth Horm IGF Res. 17:492–499. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Serrano ML, Sánchez-Gómez M, Bravo MM, Yakar S and LeRoith: Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines. Horm Metab Res. 40:661–667. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Serrano ML, Sánchez-Gómez M and Bravo MM: Cervical scrapes levels of insulin-like growth factor-II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Horm Metab Res. 42:977–981. 2010. View Article : Google Scholar | |
|
Shen MR, Hsu YM, Hsu KF, Chen YF, Tang MJ and Chou CY: Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Carcinogenesis. 27:962–971. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Steller MA, Delgado CH, Bartels CJ, Woodworth CD and Zou Z: Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res. 56:1761–1765. 1996.PubMed/NCBI | |
|
Kuramoto H, Hongo A, Liu YX, et al: Immunohistochemical evaluation of insulin-like growth factor I receptor status in cervical cancer specimens. Acta Med Okayama. 62:251–259. 2008.PubMed/NCBI | |
|
Voskuil DW, Bosma A, Vrieling A, Rookus MA and van ‘t Veer LJ: Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat. 84:225–233. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenzweig SA and Atreya HS: Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 80:1115–1124. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Dal Maso L, Augustin LS, Franceschi S, et al: Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology. 67:225–230. 2004. | |
|
Hong J, Zhang G, Dong F and Rechler MM: Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem. 277:10489–10497. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Baege AC, Disbrow GL and Schlegel R: IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis. J Virol. 78:5720–5727. 2004. View Article : Google Scholar | |
|
Berger AJ, Baege A, Guillemette T, et al: Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol. 161:603–610. 2002. View Article : Google Scholar | |
|
Harris TG, Burk RD, Yu H, et al: Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev. 17:245–248. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, Jansen-Dürr P and Zwerschke W: Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol. 20:6483–6495. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Mathur SP, Mathur RS, Underwood PB, Kohler MF and Creasman WT: Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol. 91:486–493. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma M, Satyam A, Abhishek A, Khan R, Rajappa M and Sharma A: Molecular and circulatory expression of insulin growth factors in Indian females with advanced cervical cancer. Asian Pac J Cancer Prev. 13:6475–6479. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gariglio P, Gutiérrez J, Cortés E and Vázquez J: The role of retinoid deficiency and estrogens as cofactors in cervical cancer. Arch Med Res. 40:449–465. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shai A, Brake T, Somoza C and Lambert PF: The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 67:1626–1635. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chung SH, Franceschi S and Lambert PF: Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab. 21:504–511. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Brake T and Lambert PF: Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci USA. 102:2490–2495. 2005. View Article : Google Scholar | |
|
Yoo YA, Son J, Mehta FF, Demayo FJ, Lydon JP and Chung SH: Progesterone signaling inhibits cervical carcinogenesis in mice. Am J Pathol. 183:1679–1687. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Webster K, Taylor A and Gaston K: Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins. J Gen Virol. 82:201–213. 2001.PubMed/NCBI | |
|
López-Romero R, Garrido-Guerrero E, Rangel-López A, et al: The cervical malignant cells display a down regulation of ER-α but retain the ER-β expression. Int J Clin Exp Pathol. 6:1594–1602. 2013.PubMed/NCBI | |
|
Wang WM, Chung MH and Huang SM: Regulation of nuclear receptor activities by two human papillomavirus type 18 oncoproteins, E6 and E7. Biochem Biophys Res Commun. 303:932–939. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mathur RS and Mathur SP: In vitro downregulation of growth factors by insulin-like growth factor binding protein-3 in cervical cancer. Gynecol Oncol. 91:410–415. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Piyathilake CJ, Henao OL, Macaluso M, Cornwell PE, Meleth S, Heimburger DC and Partridge EE: Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res. 64:8788–8793. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Piyathilake CJ, Badiga S, Paul P, et al: Indian women with higher serum concentrations of folate and vitamin B12 are significantly less likely to be infected with carcinogenic or high-risk (HR) types of human papillomaviruses (HPVs). Int J Womens Health. 2:7–12. 2010. View Article : Google Scholar | |
|
Warowicka A, Kwasniewska A and Gozdzicka-Jozefiak A: Alterations in mtDNA: a qualitative and quantitative study associated with cervical cancer development. Gynecol Oncol. 129:193–198. 2013. View Article : Google Scholar | |
|
Guo W, Yang D and Xu H: Mutations in the D-loop region and increased copy number of mitochondrial DNA in human laryngeal squamous cell carcinoma. Mol Biol Rep. 40:13–20. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu W, Qin W, Bradley P, Wessel A, Puckett CL and Sauter ER: Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis. 26:145–152. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gao J, Chang YS, Jallal B and Viner J: Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res. 72:3–12. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Miller BS and Yee D: Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 65:10123–10127. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hartog H, Wesseling J, Boezen HM and van der Graaf WT: The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer. 43:1895–1904. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Friedrich RE, Hagel C and Bartel-Friedrich S: Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy. Anticancer Res. 30:1641–1643. 2010.PubMed/NCBI | |
|
Arcaro A: Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol. 4:302013. View Article : Google Scholar : PubMed/NCBI | |
|
Pollak M: The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res. 18:40–50. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Samani AA, Yakar S, LeRoith D and Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 28:20–47. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Corvaia N, Beck A, Caussanel V and Goetsch L: Insulin-like growth factor receptor type I as a target for cancer therapy. Front Biosci. 5:439–450. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Baserga R: The decline and fall of the IGF-I receptor. J Cell Physiol. 228:675–679. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nakamura K, Hongo A, Kodama J, Miyagi Y, Yoshinouchi M and Kudo T: Downregulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res. 60:760–765. 2000.PubMed/NCBI | |
|
McLaughlin-Drubin ME, Meyers J and Munger K: Cancer associated human papillomaviruses. Curr Opin Virol. 2:459–466. 2012. View Article : Google Scholar | |
|
Martignani E, Miretti S, Accornero P and Baratta M: miRNAs highlights in stem and cancer cells. Mini Rev Med Chem. 11:1165–1182. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Luo M, Shen D, Zhou X, Chen X and Wang W: MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery. 153:836–847. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung TH, Man KN and Yu MY: Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle. 11:2876–2884. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M and Hoppe-Seyler F: siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene. 22:5938–5945. 2003. View Article : Google Scholar | |
|
Hall AH and Alexander KA: RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol. 77:6066–6069. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kafri T, van Praag H, Gage FH and Verma IM: Lentiviral vectors: regulated gene expression. Mol Ther. 1:516–521. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G and McMillan NA: Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther. 13:1023–1032. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Copreni E, Penzo M, Carrabino S and Conese M: Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis. Gene Ther. 11:S67–S75. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Li B, Peng C, et al: Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes. Antiviral Res. 98:305–313. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bousarghin L, Touze A, Gaud G, et al: Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther. 8:357–365. 2009. View Article : Google Scholar | |
|
Remy-Ziller C, Germain C, Spindler A, et al: Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein. Clin Vaccine Immunol. 2:147–155. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS and Brotherton JM: Human papillomavirus vaccine introduction - the first five years. Vaccine. 30:F139–F148. 2012.PubMed/NCBI | |
|
Han KT and Sin JI: DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. Clin Exp Vaccine Res. 2:106–114. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Frazer IH: Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 4:46–54. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Berraondo P, Nouzé C, Préville X, Ladant D and Leclerc C: Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res. 67:8847–8855. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Peng S, Ji H, Trimble C, et al: Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol. 78:8468–8476. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Jin HS, Park EK, Lee JM, et al: Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol. 97:559–567. 2005. View Article : Google Scholar | |
|
Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC and Paterson Y: Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 167:6471–6479. 2001. | |
|
Chandy AG, Nurkkala M, Josefsson A and Eriksson K: Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours. Vaccine. 25:6037–6046. 2007. View Article : Google Scholar | |
|
Da Silva DM, Schiller JT and Kast WM: Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine. 21:3219–3227. 2003.PubMed/NCBI |
